DavidMPariserMD

Dermatology • Norfolk, VA

Dermatopathology

Physician

Join to view full profile

Dr. Pariser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pariser's full profile

Already have an account?

Office
6160 Kempsville Cir
Ste 200
Norfolk, VA 23502
Phone+1 757-622-6315

Fax+1 757-622-7022

Education & Training

University of Miami/Jackson Health SystemResidency, Dermatology, 1973 - 1976
Virginia Commonwealth University Health SystemInternship, Transitional Year, 1972 - 1973
Virginia Commonwealth University School of MedicineClass of 1972
University of PennsylvaniaB.A., 1964 - 1968

Certifications & Licensure

VA State Medical License 1972 - 2026
FL State Medical License 1975 - 1989
American Board of Dermatology Dermatology
American Board of Dermatology Dermatopathology

Awards, Honors, & Recognition

Speaker of the Day Award 2018
Walter B. Shelley MD Leadership Award Women�s Dermatologic Society, 2018
Gold Medal American Academy of Dermatology, 2017
Honorary Membership American Academy of Dermatology, 2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Educator of the Year Award 2010, 2012
Gold Triangle Award American Academy of Dermatology, Health Community, 2002
Presidential Citation American Academy of Dermatology, 2000, 2002, 2004, 2009, 2013, 2015-2016
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Whos Who in Medicine and Healthcare Marquis Whos Who
Fellow (FAAD) American Academy of Dermatology
Fellow (FASDS) American Society for Dermatologic Surgery
Join now to see all

Clinical Trials

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Start of enrollment: 2007 Sep 01
Completed
Phase 3
Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Start of enrollment: 2007 Jan 01
Completed
Phase 2
Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus Start of enrollment: 2010 Feb 01
Unknown status
Phase 2
A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris Start of enrollment: 2011 May 01
Completed
Phase 2
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Start of enrollment: 2014 Jan 01
Terminated
Phase 3
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2014 Apr 01
Completed
Phase 2
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Study of Glycopyrronium in Axillary Hyperhydrosis Start of enrollment: 2015 Jul 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis Start of enrollment: 2017 Apr 12
Completed
Phase 1
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is Start of enrollment: 2018 Sep 17
Completed
Phase 2
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is Start of enrollment: 2019 Mar 18
Terminated
Phase 2
Clinical Investigation of Safety and Effectiveness of Emerald IPLdevice Start of enrollment: 2019 Apr 15
Completed
Not Applicable
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

427 citations
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus
Lasse R. Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, Robert Bissonnette, Peter Foley
Journal of the American Academy of Dermatology. 2007-01-01
236 citations
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kim A. Papp, Alice B. Gottlieb, Luigi Naldi, David M. Pariser, Ho
Journal of Drugs in Dermatology. 2015-07-01
95 citations
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients
Jonathan S. Zager, Brian R. Gastman, Sancy A. Leachman, Rene Gonzalez, Martin D. Fleming
BMC Cancer. 2018-02-05

Journal Articles

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results fr...
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S,�Pariser�D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Gu..., Br J Dermatol, 1/28/2019
Continued treatment with secukinumab is associated with high retention or regain of response
Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S,�Pariser�D, Lebwohl M, Sieder C, Melzer N, Reich K, Br J Dermatol, 1/10/2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice
Lebwohl M, Alexis AF, Beck LA, Block JK, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Boguniewicz M, J Drugs Dermatol, 1/1/2019
Glycopyrronium Tosylate in Pediatric Primary Axillary Hyperhidrosis: Post Hoc Analysis of Efficacy and Safety Findings by Age from Two Phase Three Randomized Controlle...
Douglass W Forsha, David M Pariser, Adelaide A Hebert, Dee Anna Glaser, William P Werschler, Pediatric Dermatology
Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of two Phase 3 randomized controlled...
Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T, J Am Acad Dermatol, 1/31/2018
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Contro...
Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA, Am J Clin Dermatol, 1/30/2018
Long-term safety results from a Phase 3 open-label study of a fixed combination halobetasol propionate 001% and tazarotene 0045% (HP/TAZ) lotion in moderate-to-severe ...
Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R, J Am Acad Dermatol, 1/15/2018
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L, Br J Dermatol, 1/10/2018
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials
Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, Drew J, Quiring J, Pariser DM, J Am Acad Dermatol, 1/9/2018
Planimetric Post-hoc analysis of women with onychomycosis from tavborole 5% phase III studies: Evidence of greater imporvements in patients with >50% baseline infec...
Pariser DM, Wendelken ME, Rycerz AM, Gellings Lowe N, Montgomery Yost J, Lipner SR, J Drugs Dermatol, 1/1/2018
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients
Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisin..., BMC Cancer, 1/1/2018
Understanding Patient Experience With Hyperhidrosis: A National Survey of 1,985 Patients
Glaser DA, Hebert A, Pieretti L, Pariser D, J Drugs Dermatol, 1/1/2018
Introducing a curriculum in ethics and professionalism for dermatology residencies
Stoff BK, Grant-Kels JM, Brodell RT, Paller AS, Perlis CS, Mostow E, Pariser D, Bercovitch L, J Am Acad Dermatol, 1/1/2018
Halobetasol 001%/Tazarotene 0045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R, J Drugs Dermatol, 1/1/2018
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 001%/Tazarotene 0045% Fixed Combination
Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R, J Drugs Dermatol, 1/1/2018
Novel Tretinoin 005% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older
Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R, J Drugs Dermatol, 1/1/2018
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Lebwohl M, J Allergy Clin Immunol Pract, 1/29/2017
Efficacy and safety of the Janus Kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study
Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, Kieras E, Parsons-Rich D, Menon S, Salganik M, Page K, Peeva E, Br J Dermatol, 1/26/2017
Apremilast for the treatment of moderate to severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
Bissonnette R, Haydey R, Rosoph L, Lynde CW, Bukhalo M, Fowler J, Delorme I, Gagn�-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser D, J Eur Acad Dermatol Venereol, 1/21/2017
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl ..., J Am Acad Dermatol, 1/1/2017
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 005% Versus Its Vehicle ...
Pariser DM, Bukhalo, M, Guenthner S Kempers S, Shideler S, Stein Gold L, Tschen E, Berg J, Ferdon MB, Dromgoole S, J Drugs Dermatol, 1/1/2017
Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects ...
Pariser DM, Krishnaraja J, Tremblay TM, Rubison RM, Love TW, McGraw III MF, J Drugs Dermatol, 1/1/2017
Dromgoole S Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 005% Versus ...
Pariser D, Bukhalo M, Guenthner S, Kempers S, Shideler S, Gold LS, Tschen E, Berg J, Ferdon MB, J Drugs Dermatol, 1/1/2017
Greater efficacy with secukinumab treatment is associate with greater psoriasis symptom improvement relief: Resuls from secukinumab clinical trials
Gottlieb AB, Strober B, Lebwohl M, Kaufmann R, Pariser DM, Narbutas R, Nyirady J, Zhao Y, Herra M, McCleod L, Odom D, Elewski BE, Journal of Psoriasis and Psoriatic Arthritis, 1/1/2017
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-...
Blauvelt A, de Bruin-Weller M, Gooderham M, Caher JC, Weisman J, Pariser DM, Simpson EL, Papp KA, Hong H Chin-Ho. Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Har..., Lancet, 1/1/2017
Join now to see all

Books/Book Chapters

Botulinum Toxins in Clinical Aesthetic Practice
Chapter: Botulinum toxin in the management of focal hyperhidrosis
Pariser DM, Glaser DAEditors: Benedetto A.CRC Press, Taylor and Francis Group, Boca Raton, FLEdition 3rd,2018
Manual of Obstetrics
Chapter: Dermatologic Complications of Pregnancy
Pariser DM, Huntley AC, Horney DAEditors: Evans AT and Niswander KR.Lippincott-Raven and Wilkins, Philadelphia, PAEdition 6th,2000
Care Management of Skin Diseases, Life Quality and Economic Impact
Chapter: Strategies for primary care physicians to manage contact dermatitis
Pariser DMEditors: Rajagopalan R, Sheretz EF, Adams RT.Marcel Dekker, Inc., New York, NY1998
Saunders Manual of Medical Practice
Pariser DM. HyperhidrosisEditors: Rakel RE.W. B. Saunders Company, Philadelphia, PA1996
Tecniche Per La Diagnosi Di Malattie Cutanee E Del Capelli
Pariser DM, Caserio RJ, Eaglstein WHMicarelli Editore, Rome, Italy1995
Techniques for Diagnosing Skin and Hair Diseases
Pariser DM, Caserio RJ and Eaglstein WHThieme-Stratton, New York, NY1986
Office Techniques for Diagnosing Skin Diseases
Eaglstein WH and Pariser DMYear Book Medical Publishers1978
Join now to see all

Abstracts/Posters

Don�t Sweat it: New Drugs for Hyperhidrosis
Pariser DM, DermFOOT CME Conference, Tysns Corner, VA, 1/13/2019
Biologics 101: The evolution of biologics
Pariser DM, DermFOOT CME Conference, Tysns Corner, VA, 1/13/2019
Scratching the surface: Psoriasis management
Pariser DM, DermFOOT CME Conference, Tysns Corner, VA, 1/13/2019
Innovations in hyperhidrosis
Pariser DM, South Beach Symposium, Miami Beach, FL, 1/9/2019
Combination therapy in managing psoriasis
Pariser DM, South Beach Symposium, Miami Beach, FL, 1/9/2019
Patient cases- psoriasis
Pariser DM, South Beach Symposium, Miami Beach, FL, 1/9/2019
Focus Session Director, Updsate on treatment of hyperhidrosis
Pariser DM, American Academy of Dermatology Annual Meeting, Washington, DC, 1/4/2019
Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with prior exposure to apremilast: results of a pooled analysis of reSURF...
Gordon K, Reich K, Pariser DM, Menter A, Tyring S,Sofen H, Rozzo S, Parno J, Li Q, La Rosa C, World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, 1/30/2018
Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast
Gordon KB, Reich K, Pariser DM, Menter A, Tyring SK, Sofen H, Rozzo SJ, Parno J, Li Q, La Rosa C, 5th World Psoriasis and Psoriatic Arthritis Conference, Internal Federation of Psorisis Associations, Stockholm, Sweeden, 1/30/2018
New and Emerging Therapies
Pariser DM, Amercan Academy of Dermatology, Chicago, IL, 1/27/2018
Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMh...
K.A. Papp, M. Gooderham, R.G. Langley, C. Leonardi, J.-P. Lacour, S. Philipp, S. Tyring, M. Bukhalo, J.J. Wu, J. Bagel, E.H. Frankel, D. Pariser, M. Flack, J. Scherer,..., Societa Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse, Verona, Italy, 1/26/2018
Clinical and Therapeutic Pearls in medical Dermatology
Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
Oral psoriasis therapy data and pearls
Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
Hyperhidrosis update
Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
Efficacy and safety of IL-23 therapies
Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
Managing the challenging hyperhidrosis patient
Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
Coding and reimbursement update
Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
Dupilumab and Concomitant Topical Corticosteroids in the Long-term Management of Moderate-to-Severe Atopic Dermatitis: Analysis of Clinical Outcomes by Race (LIBERTY A...
Pariser DM, Lockshin BN, Griffiths CEM, Maui Derm NP+PA Summer, Colorado Springs, CO, 1/23/2018
Improving your patient interactions: Dealing with the difficult patient
Pariser DM, Real world dermatology for PA�s and NP�s, Orlando, FL, 1/22/2018
Evaluating and managing seborrheic keratosis and other benign lesions
Pariser DM, Real world dermatology for PA�s and NP�s, Orlando, FL, 1/22/2018
Expert Perspectives on the Management of Moderate-to-Severe Atopic Dermatitis: Addressing Current and Emerging Therapies
Boguniewicz M, Alexis AF, Beck LA, Block J. Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser DM, Silverberg JI,,1 Lebwohl M, Real World Dermatology for PAs and NPs, Orlando, FL, 1/22/2018
A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid�Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities
Jiang SB, Kempers SE, Rich PA, Marcus SL,Piacquadio DJ, Pariser DM, DERM NP and PA Conference, Las Vegas, NV, 1/22/2018
New Options for Photodymanic Therapy
Pariser DM, Department of Dermatology, Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University, Medical College of Virginia, New York, NY, 2017; Richmond, VA, 2018, 1/21/2018
Hands-on patient demonstrations of botulinum toxin for palmar and axillary hyperhidrosis
Pariser DM, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, 1/21/2018
New Therapies for Hyperhidrosis
Pariser DM, Fall Clinical Dermatology Conference, Las Vegas, NV, 1/21/2018
Join now to see all

Lectures

Hyperhidrosis: Update on Therapeutics
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019
International Hyperhidrosis Society Hyperhidrosis Treatment and Practice Excellence
American Academy of Dermatology, Hoboken, New Jersey - 9/8/2012
Managed Care and Dermatology
Cleveland, OH, 1994; Boston, MA, 1995 - 1/29/1995
Managed and Capitated Care - Advantages and Disadvantages
San Francisco, CA - 1/31/1994
Managed Care - Gatekeepers and Capitation
San Francisco, CA - 1/30/1994
Managed Care and Managed Competition: Negotiating a Contract in Which Plans to Participate
Houston, TX - 1/24/1994
Managed Care and Managed Competition: Negotiating a Contract and In Which Plans to Participate
Houston, TX - 1/24/1994
Ethical Dilemmas of Managed Care
Philadelphia, PA - 1/22/1994
Diagnosis and Overview of Onychomycosis
Hershey, PA - 1/19/1994
Treatment of Tinea Versicolor
Hershey, PA - 1/19/1994
Management of Cutaneous Fungal Infections
Williamsburg, VA, 1994; Hershey, PA, 1994 - 1/19/1994
Uncomplicated Cutaneous Candidiasis
Hershey, PA - 1/19/1994
Treatment of Onychomycosis II - New Therapies
Hershey, PA - 1/19/1994
Treatment of Onychomycosis I - Conventional and Traditional Methods
Hershey, PA - 1/19/1994
How to Approach a Nail - Anatomy
Hershey, PA - 1/18/1994
Diagnosis and treatment of cutaneous Candida, Seborrheic Dermatitis and Tinea Versicolor
Williamsburg, VA - 1/14/1994
Relationship of Primary Care Physicians and Dermatologists in Managed Care
Williamsburg, VA - 1/14/1994
How to Manage Managed Care
Dana Point, CA - 1/13/1994
Dermatology and Capitation
White Plains, NY, 1993; Laguna Niguel, CA, 1994 - 1/12/1994
Clinical Manifestations of Fungal Infections
Flint, MI - 1/3/1994
Diagnosis and management of Skin Fungus Infections for the Primary Care Physician
Allentown, PA - 1/2/1994
How Managed Care Will Affect Your Practice
San Francisco, CA - 1/1/1994
Diagnosis and Management of Dermatophyte Infection
Alpena, MI - 1/1/1994
Effects of Finasteride on Dihydrotestosterone Content of Scalp Skin in Men with Male Pattern Baldness
1/1/1994
Topical Steroids in Mild to Severe Dermatoses
Myrtle Beach, SC - 1/29/1993
Join now to see all

Other

Primary focal hyperhidrosis
Pariser D, Smith CC
http://www.uptodate.com/contents/primary-focal-hyperhidrosis
UpToDate, Wolters Kluwer Health - 2012-08-14

Press Mentions

How to Relieve Itchy PsoriasisMarch 23rd, 2023
Novel Single-Use Patch Shows Promise for Axillary HyperhidrosisMarch 19th, 2023
Pivotal Clinical SAHARA Study Shows Candesant Biomedical's Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)March 18th, 2023
Join now to see all

Professional Memberships

American Academy of Dermatology - AAD
Fellow
American Society for Dermatologic Surgery - ASDS
Fellow